As input for the panel discussion topic "Meet the unmet needs in Precision Medicine," I would like to present the Swiss Tumor Profiler (TuPro) Study. This observational trial explores advanced strategies in precision medicine. The TuPro study focuses on integrating comprehensive molecular profiling technologies to enhance clinical decision-making in oncology. Recent advancements in next-generation sequencing (NGS) have facilitated personalized treatment options in cancer care, particularly for patients without approved treatment alternatives. However, the effectiveness of these treatments is limited, as evidenced by the modest response rates in patients and the varying efficacy of treatments like the BRAF inhibitor Vemurafenib across different cancer types. These limitations highlight the need for a more in-depth understanding of various factors, such as the tumor microenvironment, cellular heterogeneity, and cell-cell interactions.
The TuPro study addresses these challenges by offering a detailed analysis of tumor cells' molecular and functional profiles, including the composition and interactions within tumor tissues. The goal is to provide integrated treatment recommendations based on a tumor's detailed molecular profile and ex vivo drug response within a clinically relevant timeframe. This approach aims to transform current diagnostic methods and bridge the gap between complex molecular profiling and practical clinical decision-making. The study aligns with various large-scale initiatives to improve human health and stands out in its direct application to clinical oncology. TuPro and associated research projects are geared to advance the field of precision oncology by leveraging cutting-edge technologies to inform and enhance treatment strategies.
Literature | PaperPile:
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. A. Irmisch et al., Cancer Cell (2021)
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. M. H. E. Wildschut et al., Nature. Communications (2023)
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. K. Kropivsek, et al, Nature Cancer (2023)
Targeting tumor-intrinsic neural vulnerabilities of glioblastoma S. Lee et al., bioRxiv (2023)
Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency. P. Forny et al, Nature Metabolism (2023)
Rapid implementation of predictive molecular and functional --omics data enriches personalized clinical decision making in melanoma – a study of the Tumor Profiler Center. Nicola Miglino et al, submitted (2024)
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia. R. Wegmann et al. submitted (2024)
Single-cell, functional landscapes of metastatic melanoma identify actionable features for clinical intervention. S. Chevrier et al., submitted (2024)
